Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles [Seeking Alpha]
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Summary Outlook Therapeutics faces liquidity issues and delays in FDA approval for its Wet AMD therapy, leading to a downgrade from Strong Buy to Buy. The potential blockbuster market for LYTENAVA in treating Wet AMD is significant, but FDA hurdles and financial constraints pose risks. Despite high upside potential, investors face the risk of losing their entire stake due to Outlook's financial and regulatory challenges. PM Images/DigitalVision via Getty Images This is my third Outlook Therapeutics ( NASDAQ: OTLK ) article. As I will discuss, its situation is getting stickier in terms of current liquidity and timing. I am downgrading my Strong Buy rating from 06/2024's "Outlook Therapeutics: Worth A Good Strong Look After CRL"; instead, I am rating Recommended For You About OTLK Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation ConferenceGlobeNewswire
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.MarketBeat
- Outlook Therapeutics® Participates in a Virtual Investor CEO Connect SegmentGlobeNewswire
- OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell SeriesGlobeNewswire
OTLK
Earnings
- 8/14/24 - Beat
OTLK
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form SC
- 10/3/24 - Form 4
- OTLK's page on the SEC website